18Feb 2021
Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing

Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing

By implementing dynamic circulating tumor DNA (ctDNA) analysis, we explored impact of TP53 mutations on tumor evolution and resistance mechanisms to ensartinib in ALK-positive non-small-cell lung cancer (NSCLC) patients.

  • #pulmonology

Like

Save

Share